This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McMahon-Pratt, D Articles by Ruddle, N H Search for Related Content PubMed PubMed Citation Articles by McMahon-Pratt, D Articles by Ruddle, N H

Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06510.

ABSTRACT

Leishmania is a genus of parasitic protozoa capable of causing a spectrum of human diseases. The GP46/M-2 membrane glycoprotein has been demonstrated in a murine model system to elicit a protective immune response against infection with Leishmania amazonensis; in highly susceptible BALB/c mice, immunization leads to significant protection against infection. In the present study, for induction of long-term immunological effects, two recombinant vaccinia viruses, derived from the wild type and attenuated variant 48-7 and expressing the GP46/M-2 protein, were constructed; to ensure safety, we used the attenuated vaccinia virus mutant (48-7) as a live vector. Susceptible BALB/c mice immunized with either GP46/M-2-recombinant vaccinia virus were significantly protected against infection with L. amazonensis; 45 to 76% of the animals were completely protected (sterile) against a challenge inoculum of 10(3) infective organisms. The protectively immunized animals demonstrated T- and B-cell-dependent immunological responses; both lymphokine responses as well as antibody responses and long-term memory are indicative of T-cell activation. This first report of the use of a recombinant vaccinia virus to induce protection against a Leishmania infection indicates that recombinant vaccinia viruses should be of value in the design of a safe and effective vaccine against this parasitic disease.

This article has been cited by other articles:

• De Trez, C., Brait, M., Leo, O., Aebischer, T., Torrentera, F. A., Carlier, Y., Muraille, E. (2004). Myd88-Dependent In Vivo Maturation of Splenic Dendritic Cells Induced by Leishmania donovani and Other Leishmania Species. Infect. Immun. 72: 824-832 [Abstract] [Full Text]  
• Colmenares, M., Kima, P. E., Samoff, E., Soong, L., McMahon-Pratt, D. (2003). Perforin and Gamma Interferon Are Critical CD8+ T-Cell-Mediated Responses in Vaccine-Induced Immunity against Leishmania amazonensis Infection. Infect. Immun. 71: 3172-3182 [Abstract] [Full Text]  
• Coler, R. N., Skeiky, Y. A. W., Bernards, K., Greeson, K., Carter, D., Cornellison, C. D., Modabber, F., Campos-Neto, A., Reed, S. G. (2002). Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant, Leishmania major Stress-Inducible Protein 1, and Leishmania Elongation Initiation Factor Protects against Leishmaniasis. Infect. Immun. 70: 4215-4225 [Abstract] [Full Text]  
• Myung, K. S., Beetham, J. K., Wilson, M. E., Donelson, J. E. (2002). Comparison of the Post-transcriptional Regulation of the mRNAs for the Surface Proteins PSA (GP46) and MSP (GP63) of Leishmania chagasi. J. Biol. Chem. 277: 16489-16497 [Abstract] [Full Text]  
• Colmenares, M., Tiemeyer, M., Kima, P., McMahon-Pratt, D. (2001). Biochemical and Biological Characterization of the Protective Leishmania pifanoi Amastigote Antigen P-8. Infect. Immun. 69: 6776-6784 [Abstract] [Full Text]  
• Campos-Neto, A., Porrozzi, R., Greeson, K., Coler, R. N., Webb, J. R., Seiky, Y. A. W., Reed, S. G., Grimaldi, G. Jr. (2001). Protection against Cutaneous Leishmaniasis Induced by Recombinant Antigens in Murine and Nonhuman Primate Models of the Human Disease. Infect. Immun. 69: 4103-4108 [Abstract] [Full Text]  
• Handman, E. (2001). Leishmaniasis: Current Status of Vaccine Development. Clin. Microbiol. Rev. 14: 229-243 [Abstract] [Full Text]  
• Streit, J. A., Recker, T. J., Filho, F. G., Beverley, S. M., Wilson, M. E. (2001). Protective Immunity Against the Protozoan Leishmania chagasi Is Induced by Subclinical Cutaneous Infection with Virulent But Not Avirulent Organisms. J. Immunol. 166: 1921-1929 [Abstract] [Full Text]  
• Aebischer, T., Wolfram, M., Patzer, S. I., Ilg, T., Wiese, M., Overath, P. (2000). Subunit Vaccination of Mice against New World Cutaneous Leishmaniasis: Comparison of Three Proteins Expressed in Amastigotes and Six Adjuvants. Infect. Immun. 68: 1328-1336 [Abstract] [Full Text]  
• Suffia, I., Ferrua, B., Stien, X., Mograbi, B., Marty, P., Rousseau, D., Fragaki, K., Kubar, J. (2000). A Novel Leishmania infantum Recombinant Antigen Which Elicits Interleukin 10 Production by Peripheral Blood Mononuclear Cells of Patients with Visceral Leishmaniasis. Infect. Immun. 68: 630-636 [Abstract] [Full Text]  
• Webb, J. R., Campos-Neto, A., Ovendale, P. J., Martin, T. I., Stromberg, E. J., Badaro, R., Reed, S. G. (1998). Human and Murine Immune Responses to a Novel Leishmania major Recombinant Protein Encoded by Members of a Multicopy Gene Family. Infect. Immun. 66: 3279-3289 [Abstract] [Full Text]  
• Beetham, J. K., Myung, K. S., McCoy, J. J., Wilson, M. E., Donelson, J. E. (1997). Glycoprotein 46 mRNA Abundance Is Post-transcriptionally Regulated during Development of Leishmania chagasi Promastigotes to an Infectious Form. J. Biol. Chem. 272: 17360-17366 [Abstract] [Full Text]  
• Kar, S., Soong, L., Colmenares, M., Goldsmith-Pestana, K., McMahon-Pratt, D. (2000). The Immunologically Protective P-4 Antigen of Leishmania Amastigotes. A DEVELOPMENTALLY REGULATED SINGLE STRAND-SPECIFIC NUCLEASE ASSOCIATED WITH THE ENDOPLASMIC RETICULUM. J. Biol. Chem. 275: 37789-37797 [Abstract] [Full Text]